Skip to main navigation Skip to search Skip to main content

Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

  • Body, Amy (Chief Investigator (CI))
  • Day, Daphne (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date13/08/20 → 12/08/25

Keywords

  • clinical trial
  • phase 1 study
  • treatment safety
  • treatment efficacy
  • solid tumours

Clinical Trial Phase

  • Phase I